Very high quality content. Refreshing to have a strictly professional approach with minimal or no hype. Solid research coupled with great analysis

Nice start to year with 2024 trades and outlook, original and thoughtful. Also, like the guests from a variety of disciplines as well on other podcasts you do. Keep it up!

Episodes are sometimes good and sometimes really bad but the quality of the audio makes it unlistenable

Amazing how people get paid for just talking their narrative.

Whatever you are doing to edit and speed up the conversation is working poorly. You are cutting off words and making it sound like your guest is speed reading. Listen to DOOMBERG. on other podcasts to see what I mean. This is much harder to listen to at the faster rate.

I love to get deep insight with quite different perspectives for non sophisticated investors

Great podcast, different perspectives

Really enjoyed Bilal’s discussion with Jay Pelosky. I’m a huge fan of this podcast. Really smart discussions and great guests!

I have been fortunate to be a part of the dynamic Macro Hive professional community this past year. This company has raised the level of my game ten fold in multi-asset macro investing. They do this with actionable research, trade ideas, slack chat forum and a true global mindset. They continue to push the limits in macro product innovation and progressive asset class research. Combining historical, traditional and outside the box ideas. The quality and velocity of the podcasts conducted by Bilal is off the charts. The diversity of Macro topics covered will keep all audiences engaged. It’s a really fun and high quality company. I recommend this to experienced professionals, people early in their careers, students and Macro fans in general!

Thanks Macro Hive these podcasts keep getting more interesting and insightful each episode. There is always long term key themes and actionable ideas

the first two episodes were very informative if you want a deeper understanding of why's and wherefore’s of financial markets’ reactions to COVID19.